Literature DB >> 30204486

Performance of Medtronic Hybrid Closed-Loop Iterations: Results from a Randomized Trial in Adolescents with Type 1 Diabetes.

Martin de Bock1,2,3, Julie Dart2, Michael Hancock1, Grant Smith2, Elizabeth A Davis1,2,3, Timothy W Jones1,2,3.   

Abstract

This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard™ automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA1c) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA1c 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10 mmol/L) was 63.68% ± 10.74% at baseline and changed to 75.85% ± 8.49% during the study (relative Δ19%). Time spent in <2.8 mmol/L was 0.61% ± 0.79% at baseline for the control group and changed to 0.32% ± 0.31% during the study for the control group (relative Δ48%). In the intervention group, time in target glucose sensor range (3.9-10 mmol/L) was 52.15% ± 9.55% at baseline and changed to 74.32% ± 8.41% during the study (relative Δ42%). Time spent in <2.8 mmol/L was 1.07% ± 1.77% at baseline for the intervention group and changed to 0.24% ± 0.14% during the study for the intervention group (relative Δ78%). Mean sensor glucose was 8.05 ± 0.73 mmol/L and 8.22 ± 0.56 mmol/L for the control and intervention participants. SmartGuard automode exit frequency was 0.54 exits per person per day for control and 0.12 exits per person per day for the intervention. Participants were in active SmartGuard automode 97.1% and 98.8% of the time for the control and intervention, respectively. Alarm frequency was 2.1 alarms per person per day for the control arm, and 0.26 alarms per person per day in the intervention arm. Feasibility of the enhanced HCL algorithm was demonstrated with a high proportion of time spent in SmartGuard automode and target glucose range. The iterative changes resulted in less SmartGuard automode exits without compromising glycemic control.

Entities:  

Keywords:  Closed loop; Pediatrics.; Type 1 diabetes

Mesh:

Substances:

Year:  2018        PMID: 30204486     DOI: 10.1089/dia.2018.0161

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  6 in total

1.  Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump.

Authors:  Sara H Duffus; Zain Al Ta'ani; James C Slaughter; Kevin D Niswender; Justin M Gregory
Journal:  Diabetes Obes Metab       Date:  2019-12-09       Impact factor: 6.577

Review 2.  Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes.

Authors:  Rozana Ramli; Monika Reddy; Nick Oliver
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

Review 3.  Current Status and Emerging Options for Automated Insulin Delivery Systems.

Authors:  Gregory P Forlenza; Rayhan A Lal
Journal:  Diabetes Technol Ther       Date:  2022-03-14       Impact factor: 7.337

Review 4.  Artificial Pancreas Technology Offers Hope for Childhood Diabetes.

Authors:  Melissa J Schoelwer; Mark D DeBoer
Journal:  Curr Nutr Rep       Date:  2021-01-07

5.  Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.

Authors:  Jennifer L Sherr; Bruce A Buckingham; Gregory P Forlenza; Alfonso Galderisi; Laya Ekhlaspour; R Paul Wadwa; Lori Carria; Liana Hsu; Cari Berget; Thomas A Peyser; Joon Bok Lee; Jason O'Connor; Bonnie Dumais; Lauren M Huyett; Jennifer E Layne; Trang T Ly
Journal:  Diabetes Technol Ther       Date:  2019-10-29       Impact factor: 6.118

6.  Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.

Authors:  Anders L Carlson; Jennifer L Sherr; Dorothy I Shulman; Satish K Garg; Rodica Pop-Busui; Bruce W Bode; David R Lilenquist; Ron L Brazg; Kevin B Kaiserman; Mark S Kipnes; James R Thrasher; John H Chip Reed; Robert H Slover; Athena Philis-Tsimikas; Mark Christiansen; Benyamin Grosman; Anirban Roy; Melissa Vella; Richard A M Jonkers; Xiaoxiao Chen; John Shin; Toni L Cordero; Scott W Lee; Andrew S Rhinehart; Robert A Vigersky
Journal:  Diabetes Technol Ther       Date:  2021-11-16       Impact factor: 6.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.